全球多汗症治疗市场 – 行业趋势及 2030 年预测

多汗症治疗市场分析及规模

预计在预测期内，多汗症治疗市场将出现显著增长。多汗症是指患者出现与环境条件和体温调节要求无关的极度出汗问题。非处方止汗剂通常是过度出汗的第一道防线。A 型肉毒杆菌毒素是一种安全有效的局部多汗症治疗方法，其持续时间比局部治疗更长，并且不需要侵入性手术。

Data Bridge Market Research 分析了 2023-2030 年预测期内全球多汗症治疗市场的增长率。在上述预测期内，全球多汗症治疗市场的预期复合年增长率趋于 5.60% 左右。2022 年市场价值为 6.0752 亿美元，到 2030 年将增长至 9.3945 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

多汗症治疗市场范围和细分

Market Definition

Hyperhidrosis disorders are typically characterized by excessive sweating. The excess of sweat in this condition is not even certainly associated with heat or exercise; it is related or concerned to medical abnormality. The extreme sweat occurs in areas of the body such as underarms, palms, face; some people feel the sweat in their shoes and are also unrelated to body temperature. The major cause of the diseases could be the neurologic, endocrine, infectious and other systemic diseases, but healthy people are also likely to report the sufferings from Hyperhidrosis disorders.

Global Hyperhidrosis Treatment Market Dynamics

Drivers

• Increasing Strategic Partnerships

The strategic partnerships and collaborations between several market players and associations are helping in the growth of the market. For instance, in April 2021, Fortress Biotech, partner company Journey Medicals, entered into a definitive agreement to acquire Qbrexza  in the USA from Dermira, a wholly-owned subsidiary of Eli Lilly. Therefore, the market is projected to witness growth. Though, the short-term results of cosmetic and therapeutic procedures are a major factor limiting the growth of the market.

• Growing R&D Activities

The latest R&D activities associated with the market are gaining attraction globally. For instance, in October 2021, Brickell Biotech Inc. reported positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies that evaluated sofpironium bromide gel, 15% as a once-daily topical formulation in patients having primary axillary hyperhidrosis. This boosts the market growth.

Opportunities

• Increase in Hyperhidrosis Cases

As per the study published in National Library of Medicine by Jared Brackenrich in October 2021, In the U.S, the incidence of this disorder is projected to be around 3%. Emotional, psychological, social, and occupational impairment can all be caused by hyperhidrosis. Thus, growing burden of hyperhidrosis expected to boost the demand for its treatment thus increase the market growth.

• Increasing Demand of Botox

According to the article published in International Hyperhidrosis Society of October 2020, Excessive sweating of the armpits, hands, feet, head, and face and other relatively small body areas can be treated with onabotulinumtoxin A. Botox has been shown to reduce sweating by 82-87%. The effects begin to show up 2 to 4 days post treatment, with the full effects generally appearing within two weeks. Dryness lasts 4 to 12 months on average, but few studies have found that it can last up to 14 months.

Restraints/Challenges

• Side Effects of Botox

Several side effects are associated with botox. Effects such as muscle weakness, vision problems, breathing problems that are deeply affecting the patients and thus hampering the market growth.

• High Cost

The huge expenditure of the treatment methods impede the market growth. Many times, due to lack of inappropriate payment plans and special considerations by the organizations, the patients fail to adapt these high-end treatment options which in return cost heavy impact on their health. Thus, this is an important restrain that needs to be taken care of.

This global hyperhidrosis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global Hyperhidrosis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Hyperhidrosis Treatment Market

COVID-19 had a neutral impact on the market growth. According to the January 2021 published article titled, Paroxysmal hypothermia and hyperhidrosis with exacerbation after COVID‑19 infection, periods of hypothermia alternated with fever for four days. Although, after the recovery phase, episodic hyperhidrosis and hypothermia continued without fever despite the use of clonidine. Therefore, the demand for hyperhidrosis treatment has increased. According to the International Hyperhidrosis Society in May 2021, sweat could actually help prevent the transmission of COVID-19. Even in the post-pandemic era, the disease and its associated treatment continue rapidly.

Recent Development:

• In May 2022, Meruho launched Rapifort Wipes in Japan, used for the treatment of primary axillary hyperhidrosis. It is the first prescription wipe preparation in the country.
• In August 2021, Brickell Biotech, Inc. stated that the final patient had completed the Phase 3 pivotal Cardigan II study, which evaluates sofpironium bromide gel, 15% in patients with primary axillary  hyperhidrosis

Global Hyperhidrosis Treatment Market Scope

The global hyperhidrosis treatment market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Axillary Hyperhidrosis
• Palmar Hyperhidrosis
• 足底多汗症

治疗

• 口服药物
• 抗胆碱能药物
• 其他的
• 非处方止汗剂
• 外科手术
• 激光器
• 其他的

给药途径

• 口服
• 肠外
• 其他的

最终用户

• 医院
• 家庭护理
• 专业中心
• 其他的

分销渠道

• 医院药房
• 网上药店
• 零售药店

多汗症治疗市场区域分析/见解

对全球多汗症治疗市场进行了分析，并按类型、治疗、给药途径、分销渠道和最终用户提供了市场规模洞察和趋势。

全球多汗症治疗市场报告涉及的主要国家 有：北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于北美拥有良好的医疗保健基础设施、较高的人均收入以及先进手术的采用率，预计该地区将拥有最高的市场增长。

亚太地区由于研发活动和认知度的提升而占据市场主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球多汗症治疗市场份额分析

全球多汗症治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球多汗症治疗市场的关注有关。

全球多汗症治疗市场的主要参与者包括：

• 葛兰素史克公司 (英国)
• TheraVida（美国）
• Revance（美国）
• NovaMedica。（俄罗斯）
• Ulthera, Inc.（美国）
• DEMIRA eV（德国）
• Abbvie, Inc（美国）
• Fresh Tracks Therapeutics, Inc.（美国）。
• Dr. August Wolff GmbH（德国）
• Dermavant Sciences, Inc.（美国）
• Eirion Therapeutics, Inc（英国）
• 化研制药株式会社（日本）
• Intas Pharmaceuticals Ltd.（印度）
• Roivant Sciences Ltd（瑞士）

SKU-56648